Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants - Miyamoto, Sho; Arashiro, Takeshi; Adachi, Yu; Moriyama, Saya; Kinoshita, Hitomi; Kanno, Takayuki; Saito, Shinji; Katano, Harutaka; Iida, Shun; Ainai, Akira; Kotaki, Ryutaro; Yamada, Souichi; et al. (Med (New York, N.Y. : Online), 2022)
Keywords: Antibodies, Viral; BNT162 Vaccine; BNT162b2 mRNA vaccine; breakthrough infection; Clinical and Translational Report; COVID-19; COVID-19 vaccine; COVID-19 Vaccines; Humans; neutralizing antibody; Omicron variant; Postoperative Complications; SARS-CoV-2; Vaccination; BNT162b2 mRNA vaccine; Omicron variant; SARS-CoV-2; breakthrough infection; COVID-19 vaccine; neutralizing antibody; Translation to patients